Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Brenda O'Connell"'
Autor:
Jennifer Roberts, Michael Postow, Ezra Cohen, Bartosz Chmielowski, Conor Steuer, Jerry McCarter, Nora Zizlsperger, Jeff Kutok, Brenda O’Connell, Kara Page, Halle Zhang
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Externí odkaz:
https://doaj.org/article/d0d0db4d9ad0400f8259e54d45213e49
Autor:
David S. Hong, Michael Postow, Bartosz Chmielowski, Ryan Sullivan, Amita Patnaik, Ezra E.W. Cohen, Geoffrey Shapiro, Conor Steuer, Martin Gutierrez, Heather Yeckes-Rodin, Robert Ilaria, Brenda O'Connell, Joanna Peng, Guangbin Peng, Nora Zizlsperger, Anthony Tolcher, Jedd D. Wolchok
Publikováno v:
Clinical Cancer Research. :OF1-OF10
Purpose: Eganelisib (IPI-549) is a first-in-class, orally administered, highly selective PI3Kγ inhibitor with antitumor activity alone and in combination with programmed cell death protein 1/ligand 1 (PD-1/PD-L1) inhibitors in preclinical studies. T
Autor:
Jedd D. Wolchok, Anthony Tolcher, Nora Zizlsperger, Guangbin Peng, Joanna Peng, Brenda O'Connell, Robert Ilaria, Heather Yeckes-Rodin, Martin Gutierrez, Conor Steuer, Geoffrey Shapiro, Ezra E.W. Cohen, Amita Patnaik, Ryan Sullivan, Bartosz Chmielowski, Michael Postow, David S. Hong
Study IPI-549-01 progression-free survival censoring rules for efficacy analyses
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3449dda81899432179d1e7829050dfc0
https://doi.org/10.1158/1078-0432.22700464
https://doi.org/10.1158/1078-0432.22700464
Autor:
Jedd D. Wolchok, Anthony Tolcher, Nora Zizlsperger, Guangbin Peng, Joanna Peng, Brenda O'Connell, Robert Ilaria, Heather Yeckes-Rodin, Martin Gutierrez, Conor Steuer, Geoffrey Shapiro, Ezra E.W. Cohen, Amita Patnaik, Ryan Sullivan, Bartosz Chmielowski, Michael Postow, David S. Hong
Purpose:Eganelisib (IPI-549) is a first-in-class, orally administered, highly selective PI3Kγ inhibitor with antitumor activity alone and in combination with programmed cell death protein 1/ligand 1 (PD-1/PD-L1) inhibitors in preclinical studies. Th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::746d8eba95c048501f4f9a57f5e24227
https://doi.org/10.1158/1078-0432.c.6618073
https://doi.org/10.1158/1078-0432.c.6618073
Autor:
Jedd D. Wolchok, Anthony Tolcher, Nora Zizlsperger, Guangbin Peng, Joanna Peng, Brenda O'Connell, Robert Ilaria, Heather Yeckes-Rodin, Martin Gutierrez, Conor Steuer, Geoffrey Shapiro, Ezra E.W. Cohen, Amita Patnaik, Ryan Sullivan, Bartosz Chmielowski, Michael Postow, David S. Hong
Study IPI-549-01 full protocol inclusion and exclusion criteria
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::77fdad17852c392b3f16271b9f9278fa
https://doi.org/10.1158/1078-0432.22700461.v1
https://doi.org/10.1158/1078-0432.22700461.v1
Autor:
Jedd D. Wolchok, Anthony Tolcher, Nora Zizlsperger, Guangbin Peng, Joanna Peng, Brenda O'Connell, Robert Ilaria, Heather Yeckes-Rodin, Martin Gutierrez, Conor Steuer, Geoffrey Shapiro, Ezra E.W. Cohen, Amita Patnaik, Ryan Sullivan, Bartosz Chmielowski, Michael Postow, David S. Hong
Representativeness of Study Participants
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a4084b437d970e508e01b7566b4f123e
https://doi.org/10.1158/1078-0432.22700446.v1
https://doi.org/10.1158/1078-0432.22700446.v1
Autor:
Jedd D. Wolchok, Anthony Tolcher, Nora Zizlsperger, Guangbin Peng, Joanna Peng, Brenda O'Connell, Robert Ilaria, Heather Yeckes-Rodin, Martin Gutierrez, Conor Steuer, Geoffrey Shapiro, Ezra E.W. Cohen, Amita Patnaik, Ryan Sullivan, Bartosz Chmielowski, Michael Postow, David S. Hong
Study IPI-549-01 methodology and criteria for assessing MDSCs
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::847e1f3e94296cf63e20ae357040de44
https://doi.org/10.1158/1078-0432.22700458
https://doi.org/10.1158/1078-0432.22700458
Autor:
Soliman Hatem, Jeffrey Hargis, Anthony Elias, Arielle Lee, Rachel Swart, Shaker Dahkil, Alexandra Drakaki, Vu Phan, Frederic Kass, Melody Cobleigh, Sanil Babu, Katherine Tkaczuk, Brenda O'Connell, Jennifer Roberts, Nora Zizlsperger, Erika Hamilton
Publikováno v:
Cancer Research. 82:P5-16
Background: Eganelisib is a first-in-class, oral, immuno-oncology macrophage reprogramming agent. The IMpassion130 randomized trial in 1L advanced TNBC has demonstrated improved efficacy with the addition of atezo to nab-pac in patients with PD-L1+ t
Autor:
Brenda O’Connell
Publikováno v:
Ageing Masculinities in Irish Literature and Visual Culture ISBN: 9781003240532
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::47a6732e524f492df19840cbc3321e76
https://doi.org/10.4324/9781003240532-16
https://doi.org/10.4324/9781003240532-16
Autor:
Rachel Swart, Brenda O'Connell, Jennifer Roberts, Arielle Lee, Gina Newton, Erika Hamilton, Halle H. Zhang, Hatem Soliman
Publikováno v:
Cancer Research. 81:PS11-32
Purpose: The IMpassion130 randomized trial in advanced TNBC has demonstrated improved efficacy with the addition of atezo to 1L nab-pac in patients with PD-L1+ tumors. Eganelisib is a first-in-class, novel oral agent targeting tumor-associated myeloi